Autolus Therapeutics PLC Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,000,000 American Depositary Shares in Autolus Therapeutics plc, representing 5.64% of the class.

Investment firm MAK Capital and Michael A. Kaufman have reported a 12.6% beneficial ownership stake in Autolus Therapeutics plc.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,800,000 American Depositary Shares of Autolus Therapeutics plc, representing 5.94% of the class.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman jointly reported an 11.3% beneficial ownership stake in Autolus Therapeutics PLC.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman collectively reported a 10.1% beneficial ownership in Autolus Therapeutics plc.

Armistice Capital, LLC and Steven Boyd have reported a passive beneficial ownership of 5.86% in Autolus Therapeutics plc, holding 15.6 million American Depositary Shares.

Deep Track Capital and affiliates have reduced their beneficial ownership in Autolus Therapeutics plc to 0.97%, falling below the 5% threshold.

Wellington Management Group LLP and its affiliates have reported a 0.0% beneficial ownership in Autolus Therapeutics plc, indicating a full divestment of their previously held stake.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly disclosed a passive 5.8% beneficial ownership stake in Autolus Therapeutics plc, totaling 15,408,638 American Depositary Shares.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 3.8% in Autolus Therapeutics PLC as of March 31, 2025, indicating a passive investment below the 5% threshold.

Syncona Portfolio Limited and related entities, including Syncona Holdings, Syncona Investment Management, Syncona Limited, and key individuals, have filed an amended Schedule 13G, reaffirming their collective beneficial ownership of 10.8% in Autolus Therapeutics plc.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, revealing a significant passive beneficial ownership of 10.19% in Autolus Therapeutics plc as of March 31, 2025.